Introduction
P odoplanin (PDPN), the endogenous ligand of C-type lectin-like receptor-2 (CLEC-2) of platelet, (1, 2) is highly expressed not only in many tumors, including malignant brain tumor, mesothelioma, oral cancer, lung cancer, esophageal cancer, testicular tumor, and osteosarcoma (OS), (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) but also in normal cells such as lymphatic endothelial cells (LEC). (14, 15) ''Podoplanin'' was named after its expression in podocytes of kidney. (14) PDPN is also called as ''T1a,'' and it is abundant in lung type I alveolar cells. (16) We previously named it as ''Aggrus'' because PDPN possesses a platelet aggregation-inducing activity, which is associated with cancer metastasis. (17) The interaction of human PDPN (hPDPN) with CLEC-2 is mainly observed at Glu47 and Asp48 in the platelet aggregation-stimulating domain-3 (PLAG3) and the a2-6 linked sialic acid residue. (18) The sequence motif is conserved among PDPN proteins of various species. (19) CLEC-2 has a recognition motif in the form ''EDXXXT/S,'' where X is any amino acid and T (or S) contains core 1 O-glycan with a2-6 linked sialic acid + N-acetyl-d-galactosamine (GalNAc) residue. PDPN is known as a specific lymphatic endothelial marker, (20) and PDPN-CLEC-2 signaling leads to platelet aggregation, which is critical for the embryonic blood-lymphatic vascular separation. (21) In this study, we describe the development and characterization of a new anti-hPDPN monoclonal antibody (MAb), LpMab-13, which specifically binds to PLAG2/3 domains, and might serve as a novel modality to study the function of hPDPN.
CHO/hPDPN, Lec1/hPDPN, Lec2/hPDPN, and Lec8/hPDPN) using Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, MA) according to the manufacturer's instructions. (23) HEK-293T/hPDPN-knockout (KO) cell line (PDIS-2) and LN319/hPDPN-KO cell line (PDIS-6) were produced by transfecting CRISPR/Cas plasmids (Target ID: HS0000333287), which target PDPN (Sigma-Aldrich Corp., St. Louis, MO), using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories, Inc., Berkeley, CA). (24) (25) (26) The amplified hPDPN cDNA was subcloned into a pcDNA3 vector (Thermo Fisher Scientific, Inc.) and a FLAG epitope tag was added at the Cterminus. Substitutions of amino acids to alanine, glycine, serine, or valine in hPDPN were performed using a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA) with oligonucleotides containing the desired mutations. CHO-K1 cells were transfected with the plasmids using a Gene Pulser Xcell electroporation system (Bio-Rad Laboratories). CHO-K1, Lec1, Lec2, Lec8, CHO/hPDPN, Lec1/hPDPN, Lec2/hPDPN, Lec8/ hPDPN, CHO-K1/hPDPN point mutants, NCI-H226, PC-10, and P3U1 were cultured in RPMI 1640 medium, including lglutamine (Nacalai Tesque, Inc., Kyoto, Japan), and LN229, LN229/hPDPN, LN319, LN319/hPDPN-KO, HSC-2, HEK-293T, and HEK-293T/hPDPN-KO were cultured in Dulbecco's modified Eagle's medium, including l-glutamine (Nacalai Tesque, Inc.), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. The l-proline (0.04 mg/mL) was added for Lec1, Lec2, Lec8, Lec1/hPDPN, Lec2/hPDPN, and Lec8/hPDPN. LEC was cultured in endothelial cell medium EGM-2 MV supplemented with 5% FBS (Cambrex Corp.). Antibiotics, including 100 units/mL of penicillin, 100 mg/mL of streptomycin, and 25 mg/mL of amphotericin B (Nacalai Tesque, Inc.), were added to all media. Female BALB/c mice (4-weeks old) were purchased from CLEA Japan (Tokyo, Japan).
Animals were housed under pathogen-free conditions. The Animal Care and Use Committee of Tohoku University approved the animal experiments described herein. This study examined cancer patients who underwent surgery at Sendai Medical Center (27) and Yamagata University Hospital. (6, 28) Informed consent for obtaining samples and for subsequent data analyses was obtained from patients or the patient's guardian.
Hybridoma production BALB/c mice were immunized by intraperitoneal (i.p.) injection of 1 · 10 8 LN229/hPDPN cells together with Imject Alum (Thermo Fisher Scientific, Inc.). (23) After several additional immunizations, a booster injection was given i.p. 2 days before spleen cells were harvested. The spleen cells were fused with P3U1 cells using PEG1500 (Roche Diagnostics, Indianapolis, IN). The hybridomas were grown in RPMI medium with hypoxanthine, aminopterin, and thymidine selection medium supplement (Thermo Fisher Scientific, Inc.). The culture supernatants were screened using enzyme-linked immunosorbent assay (ELISA) for binding to recombinant hPDPN purified from LN229/hPDPN cells. Proteins were immobilized on Nunc MaxiSorp 96-well immunoplates (Thermo Fisher Scientific, Inc.) at 1 mg/mL for 30 minutes. After blocking with 1% bovine serum albumin (BSA) in 0.05% Tween 20/phosphate-buffered saline (PBS, Nacalai Tesque, Inc.), the plates were incubated with culture supernatant followed by 1:2000 diluted peroxidase-conjugated antimouse IgG (Dako; Agilent Technologies, Inc.). The enzymatic reaction was conducted with a 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific, Inc.). The optical density was measured at 655 nm using an iMark microplate reader (BioRad Laboratories, Inc.).
Western blot analyses
Cell lysates (5-10 mg) were boiled in SDS sample buffer (Nacalai Tesque, Inc.). The proteins were electrophoresed on 5%-20% polyacrylamide gels (Wako Pure Chemical Industries Ltd., Osaka, Japan) and were transferred onto a PVDF membrane (EMD Millipore Corp., Billerica, MA). After blocking with 4% skim milk (Nacalai Tesque, Inc.), the membrane was incubated with LpMab-13 (1 mg/mL), anti-PDPN (1 mg/mL; clone NZ-1 and clone LpMab-7), (8, 28) anti-IDH1 (1 mg/mL; clone RcMab-1 and clone RMab-3), (29) anti-FLAG (1 mg/mL; Wako Pure Chemical Industries Ltd.), or anti-b-actin (1:10,000 diluted; clone AC-15; Sigma-Aldrich Corp.), then with peroxidase-conjugated anti-mouse or anti-rat IgG (1:1000 diluted; Dako), and developed with the ImmunoStar LD Chemiluminescence Reagent (Wako Pure Chemical Industries Ltd.) using a Sayaca-Imager (DRC Co. Ltd., Tokyo, Japan).
Flow cytometry
Cell lines were harvested by brief exposure to 0.25% Trypsin/1 mM EDTA (Nacalai Tesque, Inc.).
(2) After washing with 0.1% BSA in PBS, the cells were treated with LpMab-13, NZ-1, or LpMab-7 (1 mg/mL) for 30 minutes at 4°C and followed by treatment with Oregon Green 488 goat anti-mouse or anti-rat IgG (Thermo Fisher Scientific, Inc.). Fluorescence data were collected using a Cell Analyzer EC800 (Sony Corp., Tokyo, Japan).
Determination of the binding affinity using flow cytometry LN319 (2 · 10 5 cells) was resuspended with 100 mL of serially diluted LpMab-13 (0.006-100 mg/mL) followed by secondary anti-mouse IgG (Thermo Fisher Scientific, Inc.). Fluorescence data were collected using a cell analyzer (EC800; Sony Corp.). The dissociation constants (K D ) were obtained by fitting the binding isotherms using the built-in one-site binding models in GraphPad PRISM 6 (GraphPad software, Inc., La Jolla, CA).
Immunohistochemical analyses
Four-micrometer-thick histologic sections were deparaffinized in xylene and rehydrated. Without antigen retrieval procedure, sections were incubated with 5 mg/mL of LpMab-13 for 1 h at room temperature followed by treatment with EnVision+ Kit (Dako) for 30 minutes. Color was developed using 3, 3-diaminobenzidine tetrahydrochloride (DAB; Dako) for 5 minutes and then the sections were counterstained with hematoxylin (Wako Pure Chemical Industries Ltd.).
Results

Production of a novel anti-PDPN MAb LpMab-13
Herein, we used the CasMab technology. (23) (24) (25) 27, 28, (30) (31) (32) LN229/hPDPN cells were immunized into mice to develop 156 OGASAWARA ET AL.
novel anti-hPDPN MAbs. The culture supernatants were screened using ELISA for the binding to recombinant hPDPN purified from LN229/hPDPN cells. LpMab-13 (mouse IgG 1 , kappa) was established after limiting dilution.
Characterization of LpMab-13
LpMab-13 reacted with LN229/hPDPN, not with LN229, hPDPN-negative cell in Western blot analysis (Fig. 1A) . LpMab-13 also recognized endogenous hPDPN, which is expressed in a glioblastoma cell line LN319 and a LEC in Western blot analysis (Fig. 1A) and flow cytometry (Fig. 1B) . We also performed Western blot analysis using LpMab-13 against several glycan-deficient PDPN transfectants such as Lec1/hPDPN (N-glycan deficient), Lec2/hPDPN (sialic acid deficient), and Lec8/hPDPN (O-glycan deficient). LpMab-13 reacted with CHO-K1/hPDPN, not with CHO-K1 (Fig. 1A) . Furthermore, all transfectants of glycan-deficient PDPN were detected by LpMab-13 (Fig. 1A) , showing that the epitope of LpMab-13 is independent of glycan. LpMab-13 detected endogenous hPDPN of human kidney cell line HEK-293T, oral cancer cell line HSC-2, lung squamous cell carcinoma cell line PC-10, and malignant mesothelioma cell line HCI-H226 in flow cytometry (Fig. 1B) , although hPDPN of NCI-H226 and HEK293T was not detected using Western blot analysis (Fig. 1A) . LN229 and CHO-K1, which do not express hPDPN, were not detected by LpMab-13 (Fig. 1A) , and LpMab-13 did not react with HEK-293T/hPDPN-KO and LN319/hPDPN-KO (Fig. 1B) , indicating that LpMab-13 does not recognize nonrelated antigens.
Binding affinity of LpMab-13
We next performed a kinetic analysis of the interaction of LpMab-13 with LN319 using flow cytometry. As shown in Figure 1C Total cell lysates (5 mg) were electrophoresed on 5%-20% polyacrylamide gels and transferred onto a PVDF membrane. After blocking, the membrane was incubated with 1 mg/mL of mAbs and then with peroxidase-conjugated anti-mouse IgG against LpMab-13 and AC-15 or peroxidase-conjugated anti-rat IgG against NZ-1 and RcMab-1; the membrane was detected using a Sayaca-Imager. (B) Flow cytometric analysis. Eight cell lines were treated with LpMab-13 (1 mg/mL; red) or control PBS (black) for 30 minutes at 4°C, followed by treatment with anti-mouse IgG-Oregon green. Fluorescence data were collected using a Cell Analyzer EC800. (C) Determination of binding affinity of LpMab-13 using flow cytometry. hPDPN, human PDPN; PBS, phosphate-buffered saline.
that LpMab-13 possesses moderate affinity against endogenous hPDPN.
Immunohistochemical analysis using LpMab-13
We further investigated whether LpMab-13 is useful for immunohistochemical analyses. The expression of hPDPN is observed in many cancers such as malignant brain tumor, mesothelioma, oral cancer, lung cancer, esophageal cancer, testicular tumor, and OS. (3, 5, 11, 28) In this study, we picked up several hPDPN-expressing cancers. As shown in Figure 2 , LpMab-13 stained glioblastoma (GBM; Fig. 2B, C) , oral squamous cell carcinoma (OSCC; Fig. 2E, F) , esophageal squamous cell carcinoma (Fig. 2H, I ), osteosarcoma (OS; Fig. 2K, L) , and seminoma (Fig. 2N, O) in a membranous/ cytoplasmic staining pattern. The expression of hPDPN is
FIG. 2.
Immunohistochemical analysis by LpMab-13. Glioblastoma (GBM; A-C), oral squamous cell carcinoma (OSCC; D-F), esophageal squamous cell carcinoma (ESCC; G-I), osteosarcoma (OS; J-L), seminoma (SE, M-O), and normal lung (P-R) were used in this study. Sections were incubated with 5 mg/mL of LpMab-13, followed by EnVision+ Kit, and color was developed using DAB and counterstained with hematoxylin. Hematoxylin and eosin staining was performed against each tissue (A, D, G, J, M, P). Arrowheads: microvascular endothelial cells; arrows: lymphatic endothelial cells. Scale bar: 100 mm. also observed in normal tissues such as LEC and lung type I alveolar cells. (20) LpMab-13 reacted with LEC (arrows; Fig. 2H, I ); in contrast, it did not react with vascular endothelial cells (arrowheads; Fig. 2B, C) , demonstrating that LpMab-13 is very useful for detecting LEC. Furthermore, LpMab-13 was also reactive with lung type I alveolar cells (Fig. 2Q, R) , which are not recognized by anti-hPDPN mAbs, NZ-1 and D2-40, in our previous study. (11) Epitope mapping of LpMab-13
Because LpMab-13 reacted with 38-51 amino acids of hPDPN (data not shown), we further produced several point mutants of those residues. NZ-1 was previously produced by immunizing rats with 38-51 amino acids of hPDPN. (8) To determine the LpMab-13 epitope, we first performed Western blot analysis. LpMab-13 reaction was lost in several point mutations: A42G, G45A, D48A, and D49A (Fig. 3A) . In contrast, NZ-1 did not react with M43A and D49A. These results were confirmed by flow cytometry (Fig. 3B) . Although alanine scanning is usually performed to determine the binding epitope, conversion to other amino acids has been utilized in some reports (33) (34) (35) when alanine might be included in the epitope. Therefore, we further changed Ala42 and Ala46 to other amino acids such as Ser and Val (Fig. 4) . LpMab-13 lost the reaction with A42S in the same way with A42G although it reacted with A42V. In contrast, LpMab-13 reacted with A46S and A46V in the same way with A46G. LpMab-7, a positive control against hPDPN, reacted with all point mutants (Figs. 3 and 4) . These results indicate that the minimum epitope of LpMab-13 was identified as Ala42-Asp49 of hPDPN, the epitope of which is very similar with a rat anti-hPDPN MAb NZ-1.
Discussion
We previously produced an anti-hPDPN MAb, NZ-1.
(8) NZ-1 possesses not only high specificity and sensitivity but also high-binding affinity against hPDPN to be applied for radioimmunotherapy or immunotoxin therapy. (13, 36) Another study
The epitope mapping of LpMab-13. (A) Western blot analysis. The epitopes between LpMab-13 and NZ-1 were compared. LpMab-7 was used as positive control against hPDPN. 1E6 was used as anti-FLAG tag. AC-15 (anti-b-actin) and RMab-3 (anti-IDH1) were used as internal control. Total cell lysates (10 mg) were prepared from each CHO transfectant of hPDPN mutants, electrophoresed on 5%-20% polyacrylamide gels, and transferred onto a PVDF membrane. After blocking, the membrane was incubated with 1 mg/mL of mAbs and then with peroxidase-conjugated anti-mouse IgG against LpMab-13, LpMab-7, 1E6, AC-15, and RMab-3, and peroxidase-conjugated anti-rat IgG against NZ-1; the membrane was detected using a Sayaca-Imager. (B) Flow cytometric analysis. Point mutants of hPDPN were treated with LpMab-13 (1 mg/mL; red), NZ-1 (1 mg/mL; red), LpMab-7 (1 mg/mL; red), or control PBS (black) for 30 minutes at 4°C, followed by treatment with anti-mouse or anti-rat IgG-Oregon green. Fluorescence data were collected using a Cell Analyzer EC800. CHO, Chinese hamster ovary.
confirmed the high-binding affinity of NZ-1. (37) NZ-1 is a suitable candidate for therapy against malignant gliomas, because it was highly internalized into glioma cell lines, and also well accumulated into tumors in vivo. (13) Moreover, NZ-1 inhibited the tumor cell-induced platelet aggregation and tumor metastasis by its neutralizing activity.
(2) Furthermore, NZ-1 possesses antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against hPDPNexpressing tumor cells. (38) Although a rat anti-hPDPN MAb NZ-1 possesses perfect application in all experiments such as Western blot, flow cytometry, immunoprecipitation, immunocytochemical analysis, and immunohistochemical analysis, (8, 37) the other mouse anti-hPDPN MAbs such as D2-40 (39) or 18H5 (40) have been utilized more frequently. Usually, mouse MAbs are preferred for the reason that antimouse secondary antibodies are more available for almost all experiments especially for immunohistochemical analysis. For that reason, we recently produced anti-rat PDPN MAbs (41) and anti-rabbit PDPN MAbs (42, 43) using mice. In this study, we tried to develop mouse anti-hPDPN MAbs, the epitope of which are similar with rat NZ-1 MAb.
We recently established the CasMab technology, which can produce cancer-specific MAbs although one protein in cancer cells and normal cells possesses the same amino acid sequence. (23) We used LN229/hPDPN cells, not purified recombinant proteins, for immunization to develop novel anti-PDPN MAbs. LpMab-13 detected many PDPN-expressing cancer cell lines such as glioblastoma, lung squamous cell carcinoma, OSCC, and malignant mesothelioma. LpMab-13 does not need antigen retrieval procedure to detect hPDPN in   FIG. 4 . The epitope mapping of LpMab-13. CHO transfectants of each hPDPN mutation were treated with LpMab-13 (1 mg/mL; red), NZ-1 (1 mg/mL; red), LpMab-7 (1 mg/mL; red), or control PBS (black) for 30 minutes at 4°C, followed by treatment with anti-mouse or anti-rat IgG-Oregon green. Fluorescence data were collected using a Cell Analyzer EC800.
immunohistochemical analysis, although LpMab-2 and LpMab-3, which were also produced by CasMab technology, need antigen retrieval procedure. (23, 30) Furthermore, LpMab-9 is not useful for immunohistochemistry, whereas it is very sensitive in flow cytometry or Western blot analysis, (25) indicating that the CasMab technology is not always helpful to produce mAbs for immunohistochemical analysis. Although the epitopes of D2-40 and 18H5 are very similar with those of LpMab-13, (36) D2-40 and 18H5 also need antigen retrieval procedure. NZ-1 is also useful for immunohistochemical analysis without antigen retrieval; therefore, the epitope of LpMab-13 and NZ-1 is critical for this superiority.
In conclusion, LpMab-13 could be useful for investigating the expression and function of hPDPN in cancers and normal tissues. Furthermore, different epitope-possessing antihPDPN MAbs should be established as powerful tools for uncovering the function of hPDPN in the future.
